KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma
Pembrolizumab shrank tumours in about a third of patients with recurrent or metastatic cutaneous squamous cell carcinoma, with most responses lasting beyond a year, leading to its approval as an alternative to cemiplimab.
Overview
Phase 2 study of 105 patients with recurrent or metastatic cutaneous squamous cell carcinoma, most previously treated, given pembrolizumab every three weeks.
Objective response was 34.3 percent with complete response in 3.8 percent, median duration of response not reached, median progression-free survival 6.9 months, and toxicity typical of PD-1 blockade; a later cohort in locally advanced disease responded in about half.
- Objective response 34.3 percent; median duration of response not reached.
- Median progression-free survival 6.9 months.
Pembrolizumab is an approved first-line option for advanced cutaneous squamous cell carcinoma alongside cemiplimab.
- Single-arm; lower response rate than cemiplimab in cross-trial comparison, partly reflecting more prior treatment.
Similar pages
not linked directly; found by shared links- Key paperKEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Advanced cutaneous squamous cell carcinoma, Pembrolizumab.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
- CancerCutaneous squamous cell carcinoma
Shares KEYNOTE-629, Advanced cutaneous squamous cell carcinoma, Pembrolizumab.